HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

This study tests a drug called GSK2636771 in people with advanced cancers that have a specific genetic change (PTEN mutation or deletion). The drug blocks a protein that may help these cancer cells grow. Researchers want to see if the drug can shrink tumors or stop them from grow…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 26, 2026 04:25 UTC

Targeted drug shows promise for rare BRAF-driven cancers

This study tested the drug trametinib in 35 adults with advanced cancers that have specific BRAF genetic changes (non-V600 mutations or fusions). The goal was to see if trametinib could shrink or stop cancer growth by blocking certain proteins. While the treatment may help contro…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 26, 2026 04:24 UTC

New transplant timing strategy may tame High-Risk blood cancers

This study tests a specific schedule of chemotherapy drugs (busulfan and fludarabine) followed by a donor stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. After the transplant, a drug called cyclophosphamide is given to help prevent the don…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated May 26, 2026 04:19 UTC

Targeted pill shows promise for rare genetic cancers

This study tests a daily pill called osimertinib in people with advanced cancers that have certain EGFR gene changes. The drug blocks a faulty protein that helps tumors grow. Researchers want to see if it can shrink tumors or slow the disease in 19 patients with various cancer ty…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 26, 2026 04:17 UTC

New hope for rare cancers: targeted pill shrinks tumors in early trial

This study tests a drug called binimetinib in 53 adults with advanced cancers that have a specific genetic change (NRAS mutation). The drug blocks proteins that help cancer grow. Researchers want to see if it can shrink tumors or stop them from growing. This is a phase II trial f…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 26, 2026 04:17 UTC

New vaccine aims to shield transplant patients from deadly virus

This study tests a vaccine called Triplex to see if it can prevent cytomegalovirus (CMV) infection in adults who have received a stem cell transplant. CMV is usually harmless but can be dangerous for people with weakened immune systems. The vaccine uses harmless pieces of CMV DNA…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control

Last updated May 26, 2026 04:17 UTC

Targeted drug shows promise for rare cancers with ROS1 mutation

This study tested the drug crizotinib in 4 people with advanced cancers (like lymphoma or solid tumors) that have a specific genetic change called ROS1 translocation. The drug blocks a protein that helps cancer cells grow. The goal was to see if the drug could shrink tumors or st…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 26, 2026 04:16 UTC

New drug targets Cancer's weak spot in 35-Patient trial

This study tests a drug called GSK2636771 in 35 adults with advanced cancers that have lost a protein called PTEN. The drug blocks a growth signal that these cancer cells rely on. Researchers want to see if it can shrink tumors or stop them from growing. This is a phase II trial,…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 26, 2026 04:16 UTC

New drug targets BRCA cancers in precision trial

This study tests a drug called AZD1775 in people whose advanced cancers have a BRCA gene mutation. The drug blocks a protein that cancer cells need to grow. The goal is to see if the drug can shrink tumors or stop them from growing. About 35 adults with various advanced cancers a…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 26, 2026 04:13 UTC

New hope for rare cancers: drug targets NF2 mutation

This study is for people with advanced cancers (like lymphoma or solid tumors) that have a specific genetic change called an NF2 mutation. The drug defactinib works by blocking a protein (FAK) that helps these cancer cells grow. Researchers want to see if the drug can shrink tumo…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 26, 2026 03:58 UTC

New antibody takes aim at Hard-to-Treat blood cancers

This early-phase study tests a new antibody called Hu8F4 in 72 people with advanced blood cancers like leukemia and myelodysplastic syndrome. The main goal is to find a safe dose and check for side effects. Researchers hope the antibody can slow or stop cancer growth.

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated May 26, 2026 03:57 UTC

Targeted drug shows promise for NF1-Mutated tumors

Disease control Terminated

This study tests a drug called trametinib in 50 adults with advanced cancers that have a specific genetic change called an NF1 mutation. Trametinib blocks certain proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growing. Par…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 26, 2026 03:54 UTC

New drug aimed at taming Immunotherapy's worst side effects

This study was designed to test if itacitinib can help cancer patients whose immune system attacks their own body after immunotherapy, causing side effects that steroids can't fix. The drug works by calming the overactive immune response. However, the trial was withdrawn before e…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE2 • Sponsor: Douglas Johnson • Aim: Disease control

Last updated May 22, 2026 14:05 UTC

New hope for Hard-to-Treat cancers: drug targets genetic weakness

This study tests a drug called taselisib in people whose cancer has a specific genetic change (PIK3CA mutation) but not certain other changes. The drug aims to block a protein that helps cancer grow. About 70 adults with advanced solid tumors or lymphomas that haven't responded t…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 22, 2026 14:03 UTC

Gut bacteria booster may ease transplant side effects

This early-phase study tests a probiotic called CBM588 in 36 people who have had a donor stem cell transplant for blood cancers. The goal is to see if it is safe and can help restore healthy gut bacteria, which may reduce severe diarrhea and other gut problems. Participants take …

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control

Last updated May 22, 2026 14:03 UTC

Targeted drug combo shows promise for rare BRAF-Mutated cancers

This study tests two targeted drugs, dabrafenib and trametinib, in people with advanced cancers that have a specific BRAF gene mutation (V600E or V600K). The goal is to see if the combination can shrink tumors or stop them from growing. About 44 adults with various cancer types (…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 22, 2026 14:02 UTC

Targeted drug shows promise for rare mutation-driven cancers

This study tests the drug trametinib in people with advanced cancers that have GNAQ or GNA11 gene mutations. Trametinib blocks certain proteins that help these cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from getting worse. Only 4 patients too…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 22, 2026 13:53 UTC

New combo therapy aims to boost immune attack on tumors

This early-phase study tests the safety of the immunotherapy drug atezolizumab given after a patient's own immune cells have been modified and infused back (adoptive cell transfer). It includes 40 adults with advanced blood or solid cancers that no longer respond to standard trea…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 22, 2026 13:53 UTC

Radiation after immunotherapy: a new hope for cancer control?

This study looks at whether giving radiation therapy to people whose cancer has spread or grown after immunotherapy can help control the disease. About 230 adults with various cancers will receive radiation to see if it stops or shrinks tumors. The goal is to find a safe and effe…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated May 22, 2026 13:52 UTC

New hope for Hard-to-Treat cancers: drug targets genetic weakness

This study tests a drug called palbociclib in 40 adults with advanced cancers that have extra copies of the CCND1, 2, or 3 genes. The drug blocks certain proteins that help cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse.

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 22, 2026 13:51 UTC

Targeted drug shows promise for rare Gene-Driven cancers

This study tested a drug called crizotinib in people with advanced cancers that have a specific genetic change called ALK rearrangement. The goal was to see if the drug could shrink tumors or stop them from growing. Only 5 patients took part, and the results help researchers unde…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 22, 2026 13:50 UTC

New drug shows promise for stem cell transplant complication

This study tests a drug called acalabrutinib in 51 adults with moderate-to-severe chronic graft-versus-host disease (GVHD), a complication after stem cell transplant. The goal is to see if it can control the disease when steroids have stopped working. Participants take the drug a…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control

Last updated May 19, 2026 12:01 UTC

Targeted drug shows promise for HER2-Mutated cancers

This study tests a drug called afatinib in 40 patients whose advanced cancers have a specific genetic change called a HER2 mutation. Afatinib works by blocking the HER2 protein, which may help stop cancer cells from growing. The goal is to see if the drug can shrink tumors or slo…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 18, 2026 12:13 UTC

Targeted therapy shows promise for rare HER2-Positive cancers

Disease control Terminated

This study tests a drug called ado-trastuzumab emtansine in people with advanced cancers that have too many HER2 receptors (HER2 amplification), except breast and stomach cancers. The drug combines an antibody that targets HER2 with a chemotherapy agent to kill cancer cells. Rese…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 18, 2026 12:11 UTC

Can genetically engineered goat milk stop a deadly transplant side effect?

This early-stage trial tests whether drinking milk from goats genetically modified to produce a human enzyme (lysozyme) can help prevent graft-versus-host disease (GVHD) in people with blood cancer receiving a donor stem cell transplant. About 53 participants will drink a daily a…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control

Last updated May 18, 2026 12:07 UTC

Donor cells take on stubborn virus in transplant patients

This study tests whether specially trained white blood cells from donors can treat a stubborn CMV infection in people who have had a stem cell transplant. About 49 participants will receive these cells to see if the infection clears. The goal is to control the virus when standard…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated May 18, 2026 11:59 UTC

New drug targets AKT mutations in Hard-to-Treat cancers

Disease control Terminated

This study tested a drug called AZD5363 in 35 people with advanced cancers that have a specific genetic change (AKT mutation). The drug works by blocking a protein that helps cancer cells grow. The goal was to see if the drug could shrink tumors or stop them from growing. This is…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 15, 2026 11:58 UTC

Childhood cancer immunotherapy trial pulled before starting

This study was designed to test two immunotherapy drugs, nivolumab and ipilimumab, in children and young adults with cancers that returned or didn't respond to treatment and have many genetic mutations. The goal was to see if the combination could shrink tumors or help patients l…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 13, 2026 15:59 UTC

New portable device could spot heart trouble early in childhood cancer survivors

Diagnosis Ongoing

This study looks at whether portable, easy-to-use devices can detect early signs of heart damage in childhood cancer survivors. These devices can be used at home or in a clinic, potentially catching problems sooner than standard tests. The study involves 149 participants and comp…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: NA • Sponsor: City of Hope Medical Center • Aim: Diagnosis

Last updated May 22, 2026 13:52 UTC

Donor vaccine could shield transplant patients from dangerous virus

Prevention Ongoing

This early-phase trial tests whether giving a CMV vaccine to stem cell donors can boost the recipient's immunity after transplant. About 34 blood cancer patients receiving donor stem cells are involved. The goal is to prevent CMV viremia, a common and serious viral infection, wit…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Prevention

Last updated May 26, 2026 04:19 UTC

New combo therapy aims to help cancer patients sleep better

This study tests whether combining cognitive behavioral therapy with three medications (methylphenidate, melatonin, and light therapy) can improve sleep in cancer patients. About 68 adults currently on cancer treatment who have poor sleep quality will participate. The goal is to …

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief

Last updated May 26, 2026 04:25 UTC

Cancer breathlessness study: can opioids help you walk easier?

This study tests if fast-acting opioids (fentanyl or morphine) can reduce shortness of breath during or after walking in 150 cancer patients who already take strong painkillers. Participants will take the drug or a placebo before a short walk test, and researchers will measure ch…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief

Last updated May 26, 2026 04:22 UTC

Can a natural compound soothe chemo nerve damage?

This study tests whether a natural supplement called PEA can reduce nerve pain, numbness, and tingling caused by chemotherapy in cancer patients. About 88 adults who have had these symptoms for at least 3 months will take PEA or a placebo for 8 weeks. The goal is to see if PEA im…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Symptom relief

Last updated May 26, 2026 03:55 UTC

Slow or fast? study tests opioid infusion speed for cancer pain

This study looks at how fast or slow a dose of hydromorphone (a strong painkiller) is given through an IV to cancer patients with pain. The goal is to see if the speed affects how well it controls pain and how likely it is to be misused. About 84 hospitalized cancer patients will…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE4 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief

Last updated May 26, 2026 03:55 UTC

New study aims to get cancer survivors moving

This study tests different behavioral programs to help childhood and young adult cancer survivors become more physically active and improve their diet. Participants are survivors aged 18-55 who are not very active. The goal is to see if personalized support can help them adopt he…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Symptom relief

Last updated May 22, 2026 14:04 UTC

Can a short therapy fix Cancer-Related insomnia?

This study tests whether a brief behavioral therapy (BBT-CI) or healthy eating education (HEAL) better reduces insomnia in 400 cancer patients receiving treatment. Participants have stage I-IV cancer and report sleep disturbances. The goal is to improve sleep and quality of life.

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE3 • Sponsor: University of Rochester NCORP Research Base • Aim: Symptom relief

Last updated May 22, 2026 14:02 UTC

Exercise may ease chemo nerve damage in cancer survivors

This study looks at whether exercise can reduce nerve damage symptoms caused by chemotherapy, like pain, numbness, or tingling in hands and feet. About 133 cancer patients who had nerve-damaging chemo in the past 9 months will either exercise or receive standard drug treatment. T…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: NA • Sponsor: University of Rochester NCORP Research Base • Aim: Symptom relief

Last updated May 20, 2026 11:57 UTC

Can a common mental health drug help cancer patients eat better?

This study compares two drugs—olanzapine and megestrol acetate—to see which works better for improving appetite and preventing weight loss in people with advanced cancer. About 227 patients will take one of the two medications for four weeks. The goal is to find a more effective …

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Symptom relief

Last updated May 20, 2026 11:54 UTC

Could a simple pill boost Radiation's power against brain cancer?

This early-phase study tests an oral drug called ropidoxuridine (IPdR) given alongside whole brain radiation for people whose cancer has spread to the brain. The goal is to see if the drug can make radiation work better by sensitizing tumor cells, while checking for side effects.…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief

Last updated May 19, 2026 11:48 UTC

Marijuana vs. opioids: cancer patients weigh in on pain relief

This study looks at how cancer patients view using marijuana products (THC or CBD) along with opioids for pain relief. Researchers will survey 200 patients in Texas and Arizona to understand their preferences and symptom control. The goal is to learn if adding marijuana helps pat…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief

Last updated Apr 30, 2026 15:51 UTC

New PET tracer could reveal hidden cancers

This early-phase study tests a new imaging tracer called 68Ga-FAPI-46 in 26 people with various cancers. The tracer targets cells around tumors, helping PET scans show where cancer is located. Researchers want to see how well the tracer works and compare it to standard imaging. T…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Knowledge-focused

Last updated May 26, 2026 04:26 UTC

Exercise and supplement combo tested in childhood cancer survivors at risk for diabetes

This study looks at whether a program of exercise and a dietary supplement called nicotinamide riboside (similar to vitamin B3) can improve muscle health and insulin resistance in adult survivors of childhood cancer who have prediabetes. About 20 participants will follow a 6-week…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: NA • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused

Last updated May 26, 2026 04:22 UTC

Why do some parents skip pain meds for kids with cancer?

This study looks at what parents think about the risks of using opioids to manage pain in children with cancer. Researchers want to understand why some parents give less pain medicine than prescribed or stop it early, even when their child is still in pain. About 110 parents of c…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused

Last updated May 26, 2026 04:19 UTC

Testosterone levels linked to brain health in new genetic analysis

This study looks at whether low testosterone levels increase the risk of dementia, depression, and anxiety. Researchers will analyze genetic data from large biobanks to see if certain gene variants linked to lower testosterone are also tied to these mental health conditions. The …

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused

Last updated May 26, 2026 04:16 UTC

Mask vs. screen: which doctor visit feels more caring?

This study looks at how patients with cancer perceive their doctor's empathy during the COVID-19 pandemic. It compares in-person visits where doctors wear protective equipment (PPE) to video calls where doctors do not wear PPE. About 107 adults from MD Anderson's emergency cancer…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused

Last updated May 26, 2026 04:15 UTC

Can a smartphone app get young cancer survivors moving? a new trial aims to find out.

This study compares two ways to increase physical activity in teens and young adults who have finished cancer treatment. One group uses a mobile app and social media support, while the other just wears a fitness tracker. The goal is to see which approach helps them stay active an…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Knowledge-focused

Last updated May 26, 2026 03:57 UTC

New platform seeks to break down barriers for underserved cancer patients

This study looks at why minority cancer patients often don't take part in clinical trials. Researchers will survey about 590 patients to understand their challenges and preferences. The goal is to create an educational platform that helps these patients learn about trials and fee…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: NA • Sponsor: Mayo Clinic • Aim: Knowledge-focused

Last updated May 26, 2026 03:57 UTC

Does race affect cancer immunotherapy success? new study investigates

Knowledge-focused Terminated

This study compares how well immune checkpoint inhibitors work in African American/Black and European American/White cancer patients. Researchers will collect blood, saliva, and health information from 2,100 participants to see if there are differences in side effects and treatme…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Sponsor: University of Rochester NCORP Research Base • Aim: Knowledge-focused

Last updated May 26, 2026 03:55 UTC

Brain wave study reveals if dying patients can still hear

This study uses a brain wave test (EEG) to find out if cancer patients who appear unresponsive in their final days can still hear or feel. Researchers will measure brain activity when sounds or words are played. The goal is to help families and doctors understand what patients ma…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused

Last updated May 26, 2026 03:54 UTC

Money stress in cancer care: can a navigator ease the burden?

This study tests a program where a financial navigator helps cancer patients and their partners understand insurance, set up payment plans, and find cost-saving options. The goal is to see if this support reduces financial hardship and improves quality of life. About 331 patients…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: NA • Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused

Last updated May 22, 2026 14:00 UTC

Cancer patients with nerve pain: how did COVID-19 impact their lives?

This study looks at how the COVID-19 pandemic affected the well-being of cancer patients who also have nerve pain (neuropathy). Researchers want to understand how the pandemic changed their quality of life and health outcomes. They will also compare patients who received a brain-…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused

Last updated May 22, 2026 13:55 UTC

Virtual team meetings aim to boost doctor engagement

This study looks at whether a special type of online meeting, called ECHO telementoring, can help diagnostic imaging doctors feel more connected and work more efficiently. Researchers at MD Anderson Cancer Center are testing this with 36 doctors. The goal is to see if these meeti…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused

Last updated May 22, 2026 13:54 UTC

Gene test trial aims to outsmart advanced cancers

Knowledge-focused Terminated

This study tests whether analyzing the genes in a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced or hard-to-treat cancers (solid tumors, lymphoma, or myeloma) had their tumors genetically screened. Those with specific genetic c…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused

Last updated May 22, 2026 13:51 UTC

Could cancer patients with fever be treated at home? new study explores

This study looked at cancer patients who had a fever and low white blood cells (neutropenic fever) to understand how often they had serious complications. The goal was to see if some of these patients could be safely treated at home instead of in the hospital. The study was withd…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused

Last updated May 20, 2026 12:08 UTC

Can a smartphone app make radiation treatment less confusing?

This study tests a mobile app called Oncpatient designed to help cancer patients navigate radiation therapy. Radiation treatment involves daily visits and managing side effects, which can be overwhelming. The app aims to provide easy-to-access information and guidance. Twenty adu…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: NA • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused

Last updated May 20, 2026 11:57 UTC

Team approach aims to help seniors bounce back after stem cell transplant

This study looks at whether a team of healthcare professionals can help older adults (65 and older) stay healthy and recover better after a stem cell transplant for blood cancer. About 40 participants will see multiple providers to improve their fitness before and after the trans…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Phase: NA • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused

Last updated May 20, 2026 11:56 UTC

Cancer Patients' pandemic struggles revealed in massive survey study

This study looked at how the COVID-19 pandemic impacted the well-being and quality of life of over 13,000 cancer patients and survivors. Researchers used questionnaires to learn about people's experiences, such as exposure to the virus, isolation, financial problems, and emotiona…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused

Last updated May 20, 2026 11:54 UTC

Transplant Survivors' hidden heart risk under the microscope

This study follows 350 stem cell transplant survivors to see how their heart, lungs, and muscles work together over two years. Researchers measure exercise capacity and other health markers to learn why transplant survivors have a higher risk of heart disease. Participants includ…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Sponsor: City of Hope Medical Center • Aim: Knowledge-focused

Last updated May 18, 2026 12:13 UTC

How do patients and doctors feel about telemedicine for cancer care?

This study surveys 200 patients and healthcare providers to understand their opinions on using telemedicine (video visits) for radiation oncology. Participants must be 18 or older, English-speaking, and have had at least one telemedicine visit. The goal is to measure satisfaction…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused

Last updated May 18, 2026 11:59 UTC

New study aims to spot malnutrition in older cancer patients

This study looks at how well nutritional check-ups can find malnutrition in older adults with cancer. About 180 participants will undergo special assessments to see if their nutrition affects their health and survival. The goal is to help doctors better identify and address malnu…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused

Last updated May 15, 2026 11:57 UTC

Teens with cancer help Fine-Tune symptom survey

This study tests a symptom questionnaire designed for teenagers with cancer. Researchers interview teens aged 13-17 to see if the survey is easy to use and accurately captures their symptoms. The goal is to improve the tool so doctors can better understand and manage what teens g…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused

Last updated May 14, 2026 12:03 UTC

New study aims to uncover the hidden costs of cancer

This study looks at the financial challenges people face after a cancer diagnosis. Researchers are surveying 625 English- or Spanish-speaking adults diagnosed within the past year to understand what factors contribute to financial stress. The goal is to identify targets for futur…

Matched conditions: HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM

Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused

Last updated May 08, 2026 12:03 UTC

New dosing method for Kids' cancer drug aims to reduce side effects in infants